Skip to content

Editors

Harry20Cassin20Managing20Editor-229x300

Harry Cassin
Publisher and Editor

Screen+Shot+2017-02-14+at+1.01.41+PM

Andy Spalding
Senior Editor

Jessica Tillipman

Jessica Tillipman
Senior Editor

WILLIAM B.F. STEINMAN

Bill Steinman
Senior Editor

Screen+Shot+2017-02-14+at+1.16.41+PM

Richard L. Cassin
Editor at Large

Elizabeth K. Spahn

Elizabeth K. Spahn
Editor Emeritus

Cody Worthington

Cody Worthington
Contributing Editor

Screen+Shot+2017-02-14+at+12.28.51+PM

Julie DiMauro
Contributing Editor

Screen+Shot+2017-02-14+at+12.44.07+PM

Thomas Fox
Contributing Editor

Screen+Shot+2017-02-14+at+12.46.31+PM

Marc Alain Bohn
Contributing Editor

Screen+Shot+2017-02-14+at+12.33.28+PM

Bill Waite
Contributing Editor

Screen+Shot+2017-08-18+at+6.34.39+AM

Shruti J. Shah
Contributing Editor

Screen+Shot+2017-02-14+at+1.13.40+PM

Russell A. Stamets
Contributing Editor

Screen+Shot+2017-02-14+at+3.09.39+PM

Richard Bistrong
Contributing Editor

Screen+Shot+2017-02-14+at+12.49.07+PM

Eric Carlson
Contributing Editor

Alere pays $13 million to resolve accounting fraud and FCPA offenses

Richard L. Cassin September 28, 2017

Massachusetts-based Alere Inc. will pay more than $13 million to settle charges that it bribed foreign officials and committed accounting fraud to meet revenue targets, the SEC said Thursday.

Alere subsidiaries in India and Colombia “obtained or retained business” by using distributors or consultants to make improper payments to officials of government agencies or entities under government control, the SEC said.… Continue Reading

World Bank debars units of Aussie engineer SMEC

Richard L. Cassin September 28, 2017

The World Bank Thursday said it debarred five subsidiaries of a leading Australia-based engineering firm after the bank found evidence of “inappropriate payments.” 

SMEC International Pty. Ltd., a subsidiary of SMEC Holdings Pty.… Continue Reading

Gary Giampetruzzi: Is Small Pharma next for DOJ enforcement?

Gary Giampetruzzi September 28, 2017

For decades, U.S. prosecutors have touted their big victories over big pharma for violations of U.S. laws prohibiting bribery in the U.S. (the federal Anti-Kickback Statute) and abroad (the FCPA). 

After paying tens of billions of dollars in fines and penalties, it appears that big pharma may have received the message and responded by taking compliance seriously and investing in the resources needed to identify and address risk areas.… Continue Reading